[{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/blood-immune-cell.ts","type":"changed","fields":[{"field":"tldr","before":"\"A drug that frees late-stage red cell production from TGF-beta-family braking freed 59% of transfusion-dependent MDS patients from transfusions for at least 12 weeks, against 31% with the standard erythropoietin inje...","after":"\"In COMMANDS, luspatercept, a drug that frees late-stage red cell production from TGF-beta-family braking, freed 59% of transfusion-dependent MDS patients from transfusions for at least 12 weeks, against 31% with the ..."}]},{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","commit":"65911992ce","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: haematological malignancies and immune/cell therapy","file":"src/data/key-papers/blood-immune-cell.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"authors"},{"field":"paperType"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"changedPractice"},{"field":"participants"},{"field":"links"},{"field":"cancers"},{"field":"drugs"},{"field":"targets"},{"field":"terms"},{"field":"companies"},{"field":"related"},{"field":"bottlenecks"}]}]